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The rapid spread of multidrug-resistant bacteria (MDR)
such as carbapenem-resistant (CR)-Klebsiella pneumoniae
and other Enterobacteriaceae, CR Acinetobacter baumannii
(CRAB), and MDR Pseudomonas aeruginosa has become a
public health concern, especially in some countries where
the diffusion of carbapenem-resistant microorganisms is
endemic [1].
The knowledge of the local epidemiology and the early
identification of patients at risk for MDR Gram negative
(GN) acquisition/infection are crucial for prompting an
appropriate empirical antimicrobial therapy, whose adequacy
is a key factor for reducing mortality [2].
In the absence of randomized clinical trial data, the
optimal treatment of infections caused by CR GN is a real
challenge for physicians [3]. In observational studies, combi-
nation therapy seemed to bring more survival benefits than
monotherapy for severe infections due to CR Enterobacte-
riaceae (CRE), whereas this is less clear for CRAB infec-
tions, with a recent randomized clinical trial suggesting no
advantages of colistin-meropenem combination vs. colistin
monotherapy for severe CRAB infections [4]. New agents
targeting MDR GN, showing restricted/preferential activity
against certain type of carbapenemases, seem to exert potent
activity, but should not be used indiscriminately, in line
with antimicrobial stewardship principles [5]. For instance,
while the first observational data for ceftazidime-avibactam
indicate high survival rates in case of CRE infections [6],
the possible development of resistance is of concern and
resistance strains have already been reported from different
geographic areas [7]. In case of resistance to both old and
novel agents, alternative revolutionary approaches such as
the combination of two carbapenems [8] [i.e., the double-
carbapenem (DC) regimen] might still retain an important
place in therapy, especially in patients with high risk of mor-
tality, pan-drug resistant organisms, and lack of therapeutic
options [9].
Since the choice of the best regimen for the treatment
of MDR GN remains a matter of debate [3], the contribu-
tion of both microbiology and pharmacology laboratories is
crucial for the optimization of the available treatments. In
fact, several studies suggested a correlation between the
carbapenem MICs of the MDR GN and the clinical effective-
ness, with regimens containing high-dose carbapenems being
possibly associated with better outcomes [3]. Furthermore,
clinicians should be aware that traditional antimicrobial
susceptibility reports do not longer suffice to provide optimal
information. Thus, the evolution of susceptibility profiling
that also includes synergy testing [10] or fast and molecular
microbiology is nowadays needful [2]. By using advanced
technology such as comprehensive genomic analysis, the
investigation and characterization of the genetic background
and horizontally transferable MDR resistance in GN might
be determined. However, it is also important to note that
whether or not to introduce advanced (but often also costly)
technologies into the laboratory workflow is a choice that
should always be carefully balanced locally, taking into
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account also the local availability of personnel and resources,
in order to both obtain and maximize the diagnostic advan-
tage compared to standard methods [11].
Diffusion of MDR GN has also started to affect the
community, thereby putting patients at risk of developing
uncomplicated but difficult-to-treat infections due to MDR
GN that may severely impair their quality of life and also
sometimes become life-threatening because of ineffective
initial treatment.
Innovative therapeutic strategies aiming at inhibition of
microbial growth or virulence factors of MDR GN, such as
essential oils [12] or small molecule inhibitors, are highly
attractive as they may show potential as part of antimicrobial
combination against MDR GN or reduce the severity of
clinical manifestations and improve antibacterial immune
responses. In this regard, critical components of mucosal
immune system might be involved in the prevention of
infection and, if altered in the expression, might correlate
with infection progression.
Given the complexity of management of MDR GN infec-
tions, which need to be tailored to the severity of patients’
underlying conditions and infection, to the type of MDR
GN isolates with their specific antimicrobial susceptibility
profiles, and to the knowledge of the local epidemiology, a
multidisciplinary approach involving clinicians, the labora-
tory, and clinical pharmacologists as well as an antimicrobial
stewardship program is recommended.
Among the articles received in response to the call for
papers and after a rigorous refereeing process, 6 papers were
accepted for publication in this special issue.The articles dealt
with the emerging and threatening problem of MDR in GN
microorganisms from both clinical and laboratory point of
view.
H. Frickmann et al. thoroughly discussed the use of
advanced diagnostic point-of-care options during military
operations, a peculiar setting where MDR GN may be
responsible for colonization and wound infections, as well as
transmission to close contacts.
In their review,D. S. Lee et al. explored and enlisted essen-
tial baseline aspects for dealing with community-acquired
urinary tract infections due to Escherichia coli in order to
prevent or at least delaying development of resistance.
F. Cancelli et al. showed that the double-carbapenem
regimen might represent a valid and effective therapeutic
option in patients with infections due to K. pneumoniae
carbapenemase (KPC) producing CRK. pneumoniae, includ-
ing those with bacteremic infection and more severe clinical
conditions. Of note, the clinical effectiveness was maintained
even in the presence of extremely high meropenemMIC.
In the study conducted by S. Alousi et al., a deep genetic
analysis of a strain of OXA-48 producing E. coli causing
bloodstream infection was performed, thus highlighting the
need of comprehensive genomic characterization of MDR
GN for infection control and antimicrobial stewardship
purposes.
In the paper by A. B. Sheremet et al., the authors showed
the ability of a new small molecule, Fluorothiazinon, inhibit-
ing type three secretion system of someGram-negative bacte-
ria, to reduce bacterial load and decrease lung pathology and
systemic inflammation in a mouse model of lung infection
due to drug-resistant P. aeruginosa. The reduced mortality
rate of mice treated with Fluorothiazinon strongly suggested
a potential use of this molecule as a therapeutic approach for
the pulmonary treatment of MDR P. aeruginosa infections.
The review of Y.-A. Tsou et al. deals with the role of
BPIFA1 (bactericidal/permeability-increasing fold 4 contain-
ing family A, member 1), a protein of innate immune system
expressed in the upper airway and nasopharyngeal region
including the trachea and nasal epithelium, that exhibits
a bactericidal and antibiofilm activity against both Gram-
positive andGram-negative bacteria. By binding LPS, BPIFA1
is also able to inhibit the growth of P. aeruginosa and K.
pneumoniae.
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